Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small-molecule drugs for the treatment of patients with cancer. Array is evolving into a late-stage development company with two wholly-owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (in collaboration with InterMune/Roche), which have the potential to begin Phase 3 or pivotal trials by the end of the 2013 calendar year.